ZURA Zura Bio Limited
$5.21▼ -3.16%
Healthcare
Other
After hours
$5.45▲ +4.61%
Sep 11, 7:50 PM ET
Volume 1.42M
Avg Volume (10D) 1.41M
Key Metrics & Fundamentals
Market Cap
$499.27M
P/E Ratio
–
Div Yield
–%
52W Range
1.88 - 7.44
% vs 50 MA
-3.60%
% vs 200 MA
2.07%
RSI-14
43.2
MACD Histogram
-0.0500
Beta (1Y vs SPY)
1.83
Free Cash Flow
-$20.93M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$29.31M
COGS
–
Operating Exp
$29.32M
Operating Income
-$29.32M
EBIT
-$29.32M
Pretax Income
-$26.39M
Net Income
-$26.30M
EPS (Diluted)
-0.21
Price & Volume History
Loading chart…
Recent News
Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply
Insider Monkey · Sep 11, 2026 5:35 AM
Zura Bio to Participate in the Cantor Global Healthcare Conference
Business Wire · Aug 31, 2026 8:30 PM
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Aug 21, 2026 11:57 PM
Wedbush Adjusts Zura Bio Price Target to $22 From $15, Maintains Outperform Rating
MT Newswires · Aug 11, 2026 12:37 PM
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Business Wire · Aug 11, 2026 11:30 AM
William Blair Starts Zura Bio (ZURA) at Outperform
Insider Monkey · Jul 14, 2026 6:09 PM
William Blair Initiates Zura Bio at Outperform
MT Newswires · Jul 8, 2026 12:24 PM
Tenaya Therapeutics Names Eric Hyllengren CFO
MT Newswires · Jun 29, 2026 1:09 PM
Zura Bio Exceeds Enrollment Targets for Phase 2 Trials in Hidradenitis Suppurativa, Systemic Sclerosis
MT Newswires · Jun 29, 2026 12:29 PM
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
Business Wire · Jun 29, 2026 11:30 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ZURA's money flow as a full page
Social Sentiment
Avg -0.30 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.